PMID- 20660333
OWN - NLM
STAT- MEDLINE
DCOM- 20100820
LR  - 20220316
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 134
IP  - 2
DP  - 2010 Aug
TI  - Achieving 95% cross-methodological concordance in HER2 testing: causes and 
      implications of discordant cases.
PG  - 284-92
LID - 10.1309/AJCPUQB18XZOHHBJ [doi]
AB  - We were interested in determining our concordance between fluorescence in situ 
      hybridization (FISH) and a previously validated immunohistochemical HER2 assay to 
      identify possible reasons for discordance and to determine if all reasons for 
      discordance were addressed by the American Society of Clinical Oncology/College 
      of American Pathologists guidelines. We reviewed 697 cases (2004-2007) in which 
      HER2 immunohistochemical and FISH testing were concurrently done. Overall 
      concordance between nonequivocal immunohistochemical and FISH results was 96%. Of 
      the 19 discordant cases, 13 (68%) were interpreted as positive 
      immunohistochemically but negative by FISH. The primary reason for this 
      discordance was immunohistochemical interpretation. Weak stain intensity, 
      granular staining, and interpretation in areas of crush artifact were identified 
      as the most common issues. Of the 6 cases interpreted as immunohistochemically 
      negative and FISH-positive, 2 were from patients known to be receiving 
      trastuzumab at the time of biopsy, 1 was very close to the FISH equivocal 
      category, and 4 cases had fewer than 1.5 CEP17 signals per cell (1 patient in 
      this group was also receiving trastuzumab). Focusing on issues with HER2 
      immunohistochemical interpretation can improve concordance rates for 
      immunohistochemically positive cases, but biologic reasons may explain some 
      discordant immunohistochemically negative cases.
FAU - Grimm, Erin E
AU  - Grimm EE
AD  - University of Washington Medical Center, Seattle, WA 98195, USA.
FAU - Schmidt, Rodney A
AU  - Schmidt RA
FAU - Swanson, Paul E
AU  - Swanson PE
FAU - Dintzis, Suzanne M
AU  - Dintzis SM
FAU - Allison, Kimberly H
AU  - Allison KH
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
CIN - Am J Clin Pathol. 2010 Aug;134(2):183-4. PMID: 20660318
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/therapeutic use
MH  - Biomarkers, Tumor/*analysis/genetics
MH  - Breast Neoplasms/drug therapy/genetics
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Practice Guidelines as Topic
MH  - Receptor, ErbB-2/*analysis/biosynthesis/genetics
MH  - Reproducibility of Results
MH  - Trastuzumab
EDAT- 2010/07/28 06:00
MHDA- 2010/08/21 06:00
CRDT- 2010/07/28 06:00
PHST- 2010/07/28 06:00 [entrez]
PHST- 2010/07/28 06:00 [pubmed]
PHST- 2010/08/21 06:00 [medline]
AID - 134/2/284 [pii]
AID - 10.1309/AJCPUQB18XZOHHBJ [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2010 Aug;134(2):284-92. doi: 10.1309/AJCPUQB18XZOHHBJ.